Please login to the form below

Not currently logged in


This page shows the latest Quad news and features for those working in and with pharma, biotech and healthcare.

ViiV takes two-drug cocktail for first-line HIV into phase III

ViiV takes two-drug cocktail for first-line HIV into phase III

HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are expected to be

Latest news

  • Aurobindo joins Patent Pool

    Quad (a combination of the three drugs and tenofovir).

  • Gilead agrees HIV patent pool deal

    as a combination pill to be called Quad.

  • Gilead's HIV drug meets phase III endpoint

    Gilead is studying the use of elvitegravir as part of a separate investigational fixed-dose, single-tablet "Quad" regimen. ... Quad pill," said Dr Norbert Bischofberger, executive vice president, R&D and chief scientific officer, Gilead Sciences. .

  • A competitive edge

    An exciting new four-in-one fixed-dose tablet, known as "Quad", has been developed by Gilead Sciences. ... CROI. These results demonstrated that the Quad regimen exhibited antiretroviral activity comparable to that of Atripla.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....